Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 7 von insgesamt 7
- Rekrutierung läuftA Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumor Resection ( ADAURA2 )Molekulare Marker
- Rekrutierung läuftRadiation during Osimertinib Treatment: a Safety and Efficacy Cohort studyMolekulare Marker
- Rekrutierung läuftA single arm phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in combination with cetuximab in subjects with unresectable stage III or stage IV cutaneous squamous cell carcinoma (cSCC)IndikationenMolekulare Marker
- Rekrutierung läuftFirst Line Ipilimumab+Nivolumab Combined with two cycles of Chemotherapy in NSCLC [FINN]
- Rekrutierung läuftA Randomized, Double-blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) ParticipantsMolekulare Marker
- Rekrutierung läuftPANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients With EGFR Mutation-Positive Locally Advanced or Advanced NSCLCMolekulare Marker
- Rekrutierung läuftEfficacy Comparison of Dostarlimab Plus Chemotherapy vs Pembrolizumab plus Chemotherapy in Participants with metatstatic non-squamous non-small Cell Lung